Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis | Zendy

Qian Miao | Zendy; Xiaobin Zheng | Zendy; Longfeng Zhang | Zendy; Kan Jiang | Zendy; Wu B | Zendy; Gen Lin | Zendy

Open Access

Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis

Author(s) -

Qian Miao,

Xiaobin Zheng,

Longfeng Zhang,

Kan Jiang,

Wu B,

Gen Lin

Publication year - 2020

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-20-2086

Subject(s) - medicine , pemetrexed , intrathecal , refractory (planetary science) , lung cancer , oncology , metastasis , chemotherapy , cancer , surgery , cisplatin , physics , astrobiology

Leptomeningeal metastasis (LM) is a fatal complication, and its incidence is increasing in non-small cell lung cancer (NSCLC). Refractory LM (rLM) has become problematic due to the lack of uniform definition and standardized treatment guidelines. In this study, we assessed the efficacy and safety of multiple therapy based on intrathecal pemetrexed (IP) in patients with rLM in NSCLC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research